Optinose AS
🇳🇴Norway
Clinical Trials
3
Active:1
Completed:2
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Adults With Autism Spectrum Disorder
Phase 1
Completed
- Conditions
- Autism Spectrum Disorder
- Interventions
- Drug: PlaceboDevice: OptiNose Breath Powered Bi
- First Posted Date
- 2015-04-10
- Last Posted Date
- 2016-09-27
- Lead Sponsor
- OptiNose AS
- Target Recruit Count
- 17
- Registration Number
- NCT02414503
- Locations
- 🇳🇴
NORMENT, KG Jebsen Centre for Psychosis Research - TOP Study, Oslo, Norway
Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Healthy Adults
Phase 1
Completed
- Conditions
- Healthy Male Adults
- Interventions
- Drug: 1 IU intravenous oxytocinDrug: Placebo
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2014-04-23
- Lead Sponsor
- OptiNose AS
- Target Recruit Count
- 19
- Registration Number
- NCT01983514
- Locations
- 🇳🇴
Norwegian Centre for Mental Disorders Research (NORMENT), KG Jebsen Centre for Psychosis Research - TOP Study, Oslo, Norway
News
No news found